| Literature DB >> 32364348 |
Abstract
The aim of this study was to determine the efficacy of oral splints in reducing the intensity of pain in patients with temporomandibular joint dysfunction in both short and long-term treatment durations. Electronic databases, Cochrane Library, MEDLINE via PubMed, Web of Science, Egyptian Knowledge Bank, and EMBASE were searched for randomized controlled trials comparing different types of splints to non-occluding splints, behavioral therapy, pharmacotherapy, counseling, and no treatment. The risk of bias was assessed by using Cochrane risk of bias recommendations. Fixed and random effects were used to summarize the outcomes. The effect estimates were expressed as standardized mean differences (SMD) or risk ratios with a 95% confidence interval (CI). Subgroup analyses were carried out according to the treatment duration. Twenty-two studies met the inclusion criteria. A meta-analysis of short-term studies up to three months revealed no significant difference between the study groups. However, long-term studies exhibited a significant difference in pain reduction in favor of the control group. Total analysis revealed that the control group resulted in significant pain reduction (SMD 0.14, 95% CI 0.05-0.23, P=0.002, I2=0%). Oral splints are not effective in reducing pain intensity or improving function in patients with temporomandibular joint dysfunction.Entities:
Keywords: Meta-analysis; Occlusal splints; Pain; Review
Year: 2020 PMID: 32364348 PMCID: PMC7222619 DOI: 10.5125/jkaoms.2020.46.2.87
Source DB: PubMed Journal: J Korean Assoc Oral Maxillofac Surg ISSN: 1225-1585
Fig. 1Flow chart diagram. Adapted from the article of Moher et al. (PLoS Med 2009;6:e1000097)[38] in accordance with the Creative Commons Attribution license. (RCT: randomized controlled trial, MMO: maximum mouth opening)
Summary of the included studies
| Study (first author) | Publication year | Diagnostic mean | Diagnosis | Pain measurement tool | Study splint type | Control | No. of participants | Follow-up period |
|---|---|---|---|---|---|---|---|---|
| Minakuchi[ | 2001 | Clinical | DD | VAS | OS | NSAID | 48 | 4 wk |
| Minakuchi[ | 2001 | Clinical | DD | VAS | OS | No treatment | 46 | 4 wk |
| Alencar Jr[ | 2009 | Clinical | MPD | SSI | Soft splint | NOS | 28 | 1 mo |
| Alencar Jr[ | 2009 | Clinical | MPD | SSI | Hard splint | NOS | 28 | 1 mo |
| Haketa[ | 2010 | Clinical | DD | VAS | OS | Exercise | 44 | 4 wk |
| Niemelä[ | 2012 | RDC/TMD | MPD | VAS | SS | Counseling | 76 | 1 mo |
| Giannakopoulos[ | 2016 | RDC/TMD | MPD | NRS | Soft splint | No treatment | 24 | 2 wk |
| Hasanoglu Erbasar[ | 2017 | RDC/TMD | MPD | VAS | NTI-tss | Counseling | 40 | 3 wk |
| Hosgor[ | 2017 | RDC/TMD | DD | VAS | SS | NSAID | 20 | 1 mo |
| Giannakopoulos[ | 2018 | RDC/TMD | MPD | NRS | Michigan splint | Exercise | 42 | 2 wk |
| Raphael[ | 2001 | RDC/TMD | MPD | PI | Hard splint | NOS | 63 | 6 wk |
| Carmeli[ | 2001 | Clinical | DD | PI | Soft splint | Exercise | 36 | 5 wk |
| Minakuchi[ | 2001 | Clinical | DD | VAS | OS | NSAID | 48 | 2 mo |
| Alencar Jr[ | 2009 | Clinical | MPD | SSI | Soft splint | NOS | 28 | 2 mo |
| Alencar Jr[ | 2009 | Clinical | MPD | SSI | Hard splint | NOS | 28 | 2 mo |
| Shedden Mora[ | 2013 | RDC/TMD | DD | VAS | OS | Cognition | 56 | 2 mo |
| Giannakopoulos[ | 2016 | RDC/TMD | MPD | NRS | Soft splint | No treatment | 24 | 6 wk |
| Hasanoglu Erbasar[ | 2017 | RDC/TMD | MPD | VAS | NTI-tss | Counseling | 40 | 6 wk |
| Haketa[ | 2010 | Clinical | DD | VAS | OS | Exercise | 44 | 8 wk |
| Wahlund[ | 2003 | RDC/TMD | MPD | PI | SS | BI | 81 | 3 mo |
| Wahlund[ | 2003 | RDC/TMD | MPD | PI | SS | Relaxation | 81 | 3 mo |
| Truelove[ | 2006 | RDC/TMD | MPD | PI | Hard splint | Self-care | 108 | 3 mo |
| Truelove[ | 2006 | RDC/TMD | MPD | PI | Soft splint | Self-care | 110 | 3 mo |
| Wassell[ | 2006 | Clinical | MPD | VAS | SS | NOS | 72 | 3 mo |
| Alencar Jr[ | 2009 | Clinical | MPD | SSI | Soft splint | NOS | 28 | 3 mo |
| Alencar Jr[ | 2009 | Clinical | MPD | SSI | Hard splint | NOS | 28 | 3 mo |
| Wahlund[ | 2015 | RDC/TMD | MPD | NRS | SS | Relaxation | 57 | 3 mo |
| Conti[ | 2015 | RDC/TMD | DD | PI | ARS | Counseling | 21 | 3 mo |
| Conti[ | 2015 | RDC/TMD | DD | PI | NTI-tss | Counseling | 21 | 3 mo |
| Hosgor[ | 2017 | RDC/TMD | DD | VAS | SS | NSAID | 20 | 3 mo |
| Giannakopoulos[ | 2018 | RDC/TMD | MPD | NRS | SS | Exercise | 42 | 3 mo |
| Kokkola[ | 2018 | RDC/TMD | MPD | OHIP | SS | Counseling | 39 | 3 mo |
| Shedden Mora[ | 2013 | RDC/TMD | DD | VAS | SS | Cognition | 56 | 6 mo |
| Katyayan[ | 2014 | RDC/TMD | MPD | VAS | SS | Counseling | 80 | 6 mo |
| Wahlund[ | 2015 | RDC/TMD | MPD | NRS | SS | Relaxation | 22 | 6 mo |
| Hosgor[ | 2017 | RDC/TMD | DD | VAS | SS | NSAID | 20 | 6 mo |
| Kokkola[ | 2018 | RDC/TMD | MPD | OHIP | SS | Counseling | 35 | 6 mo |
| Truelove[ | 2006 | RDC/TMD | MPD | PI | Hard splint | Self-care | 113 | 1 yr |
| Truelove[ | 2006 | RDC/TMD | MPD | PI | Soft splint | Self-care | 103 | 1 yr |
| Qvintus[ | 2015 | RDC/TMD | MPD | VAS | SS | Counseling | 46 | 1 yr |
| Wassell[ | 2006 | Clinical | MPD | VAS | SS | No treatment | 39 | 1 yr |
| Kokkola[ | 2018 | RDC/TMD | MPD | OHIP | SS | Counseling | 43 | 1 yr |
| Ekberg[ | 2004 | Clinical | MPD | VAS | SS | NOS | 40 | 1 yr |
(DD: disk displacement, VAS: visual analogue scale, OS: occlusal splint, NSAID: nonsteroidal antiinflammatory drugs, MPD: myofascial pain dysfunction, SSI: symptom severity index, NOS: non-occluding splint, RDC/TMD: research diagnostic criteria of temporomandibular dysfunction, SS: stabilizing splint, NRS: numeric rating scale, NTI-tss: nociceptive trigeminal inhibition-tension suppression system, PI: pain intensity, BI: brief information, ARS: anterior reposition splint, OHIP: oral health impact profile)
Summary of the included studies of short- and long-term maximum mouth opening (MMO) subgroup analysis
| Study (first author) | Publication year | Diagnostic mean | Diagnosis | Pain measurement tool | Study splint type | Control | No. of participants |
|---|---|---|---|---|---|---|---|
| Carmeli[ | 2001 | Clinical | DD | MM | Soft splint | Exercise | 36 |
| Minakuchi[ | 2001 | Clinical | DD | MM | Flat OS | NSAID | 50 |
| Minakuchi[ | 2001 | Clinical | DD | MM | Flat OS | No treatment | 46 |
| Niemelä[ | 2012 | RDC/TMD | MPD | MM | SS | Counseling | 76 |
| Gomes[ | 2014 | Clinical | MPD | MM | OS | No treatment | 28 |
| Gomes[ | 2014 | Clinical | MPD | MM | OS | Massage | 28 |
| Wassell[ | 2006 | AAOFP | MPD | MM | SS | NOS | 39 |
| Wassell[ | 2006 | AAOFP | MPD | MM | SS | NOS | 72 |
| Wahlund[ | 2003 | RDC/TMD | MPD | MM | OS | BI+relaxation | 83 |
| Wahlund[ | 2003 | RDC/TMD | MPD | MM | SS | BI+relaxation | 83 |
| Wahlund[ | 2015 | RDC/TMD | MPD | MM | SS | Relaxation | 57 |
| Conti[ | 2015 | Clinical | DD | MM | SS | Relaxation | 22 |
| Conti[ | 2015 | Clinical | DD | MM | ARS | Counseling | 21 |
| Conti[ | 2015 | Clinical | DD | MM | NTI-tss | Counseling | 21 |
(DD: disk displacement, MM: inter-incisal opening in millimeters, OS: occlusal splint, NSAID: nonsteroidal antiinflammatory drugs, RDC/TMD: research diagnostic criteria of temporomandibular dysfunction, MPD: myofascial pain dysfunction, SS: stabilizing splint, BI: brief information, NTI-tss: nociceptive trigeminal inhibition-tension suppression system, AAOFP: American Academy of Orofacial Pain, ARS: anterior reposition splint, NOS: non-occluding splint)
Fig. 4Forest plot result of comparisons of the splint group vs control group in maximum mouth opening at both short and long term durations according to the total subgroup analysis. (SD: standard deviation, CI: confidence interval, df: degree of freedom)
Fig. 5Funnel plot comparison: splint group vs control group in continuous pain assessment to detect publication bias of the studies. (SE: standard error, SMD: standardized mean difference)